SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 6

Analysis of blood gas beyond bicarbonate in outpatients with stage 3–5 chronic kidney disease

[Evre 3–5 kronık böbrek hastali˘gi olanlarda bıkarbonatin ötesınde kan gazi analızı]

Merve AKTAR
Gizem YILDIRIM
Ali Nazmi Can DOĞAN
Ali SEREL
Erhan TATAR
İlter BOZACI
Alev MAHŞER
Pages
891–898
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thepatients in group 1 (n: 130) (Be

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Metabolic acidosis is a common disorder seenin course of chronic kidney disease (CKD).
📊
Key Findings & Data:In this study, weaimed to investigate the association of Base excess (BE),Anion gap (AG) and Delta Ratio with progression of CKD,renal replacement therapy (RRT) requirement and mortalityin patients with stage 3–5 CKD.Methods: A total of 212 patients with stage 3–5 CKD wereincluded in this study.
💡
Conclusion & Impact:Thepatients in group 1 (n: 130) (Be
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Metabolic acidosis is a common disorder seenin course of chronic kidney disease (CKD). In this study, weaimed to investigate the association of Base excess (BE),Anion gap (AG) and Delta Ratio with progression of CKD,renal replacement therapy (RRT) requirement and mortalityin patients with stage 3–5 CKD.Methods: A total of 212 patients with stage 3–5 CKD wereincluded in this study. Patients were divided into twogroups according to the baseline BE level. Patients werealso grouped according to the delta ratio such as non- AG,High AG and mixed type.Results: Mean BE level was significantly lower (−4.7 ± 4.0vs. −3.3 ± 4.3; p=0.02) in patientswith CKD progression. Thepatients in group 1 (n: 130) (Be

Özet

Giriş: Metabolik asidoz, kronik böbrek hastalığının (KBH) seyri sırasında sık görülen bir bozukluktur. Bu çalışmada, evre 3–5 kronik böbrek hastalarında Baz açığı (BA), anyon gap (AG) ve delta oranlarının hastalık progresyonu, renal replasman tedavi (RRT) ihtiyacı ve mortalite ile ilişkisini incelemeyi amaçladık. Metod: Toplam 212 evre 3–5 kronik böbrek hastası çalışmaya dahil edildi. Hastalar bazal BA düzeylerine göre iki gruba ayrıldı. Hastalar ayrıca delta oranlarına göre anyon gap olmayan, yüksek anyon gapli ve karışık tip olarak da gruplandırıldı. Sonuçlar: KBH progresyonu gösterenlerde ortalama BA seviyesi anlamlı şekilde (−4.7 ± 4.0 vs. −3.3 ± 4.3; p=0.02) düşüktü. Grup-1 (n: 130) (Be

🔖

Cite This Article

AKTAR, M., YILDIRIM, G., DOĞAN, A. N. C., SEREL, A., TATAR, E., BOZACI, İ., MAHŞER, A. (2022). Analysis of blood gas beyond bicarbonate in outpatients with stage 3–5 chronic kidney disease. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 6, 891–898. https://ajindex.com/articles/620739

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Chen W, Abramowitz MK. Advances in management of chronic metabolic acidosis in chronic kidney disease. Curr Opin Nephrol Hypertens 2019;28:409–16
  2. Di lorio BR, Bellasi A, Raphael KL, Santoro D, Aucella F, Garofano L, et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol 2019;32:989–1001
  3. Alva S, Divyashree M, Kamath J, Prakash PS, Prakash KS. A study on effect of bicarbonate supplementation on the progression of chronic kidney disease. Indian J Nephrol 2020;30:91–7
  4. Kim HJ, Kang E, Ryu H, Han M, Lee KB, Kim YS, et al. Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: results from the KNOW-CKD Study. Sci Rep 2019;9:16139
  5. Abe M, Akaishi T, Shoji M, Yamaguchi T, Miki T, Satoh F, et al. Renoprotective effects of oral alkalizing agents in chronic kidney disease aciduria: protocol for a randomized cohort study. BMC Nephrol 2020;21:144
  6. Laboux T, Azar R. Dietary control of metabolic acidosis in chronic kidney disease. Nephrol Ther 2019;15:491–7
  7. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. J Am Med Assoc 2019;322:1294–304
  8. Frassetto L, Banerjee T, Powe N, Sebastian A. Acid balance, dietary acid load, and bone effects-A controversial subject. Nutirents 2018;10:517
  9. Jean G, Chazot C. Complications and treatment of mineral bone disorders in chronic kidney disease. Nephrol Ther 2019;15: 242–58
  10. Jorgetti V, Drüeke TB, Ott SM. Role of proton receptor OGR1 in bone response to metabolic acidosis? Kidney Int 2016;89: 529–31
  11. Carre JE, Affourtit C. Mitochondrial activity and skeletal muscle insulin resistance in kidney disease. Int J Mol Sci 2019;20:2751
  12. Hanna RM, Ghobry L, Wassef O, Rhee CM, Kalantar-Zadeh K. A practical approach to nutrition, protein-energy wasting, sarcopenia, and cachexia in patients with chronic kidney disease. Blood Purif 2020;49:202–11
  13. Meyer F, Valentini L. Disease-related malnutrition and sarcopenia as determinants of clinical outcome. Visc Med 2019;35:282–91
  14. Kittiskulnam P, Srijaruneruang S, Chulakadabba A, Thokanit NS, Praditpornsilpa K, Tungsanga K, et al. Impact of serum bicarnonate levels on muscle mass and kidney function in predialysis chronic kidney disease patients. Am J Nephrol 2020;51: 24–34
  15. Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. Am J Kidney Dis 2019;74:263–75
  16. Schricker S, Schanz M, Alscher MD, Kimm